Supervised exercise training improves exercise cardiovascular function in idiopathic pulmonary fibrosis

European Journal of Physical and Rehabilitation Medicine

Volumn 53, Issue 2, 2017, Pages 209-218

  Vainshelboim, Baruch ^a,b,c   Kramer, Mordechai R ^a,d   Fox, Benjamin D ^a,d   Izhakian, Shimon ^a   Sagie, Alexander ^a,d   Oliveira, José ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PORTO   (Portugal)

^c STANFORD UNIVERSITY   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Echocardiography; Exercise; Interstitial lung disease; Rehabilitation

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; BLOOD; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HEART VENTRICLE; HEART VENTRICLE FUNCTION; HUMAN; ISRAEL; KINESIOTHERAPY; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; ECHOCARDIOGRAPHY, DOPPLER; EXERCISE TEST; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; ISRAEL; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION;

EID: 85019875617     PISSN: 19739087     EISSN: 19739095     Source Type: Journal    
DOI: 10.23736/S1973-9087.16.04319-7     Document Type: Article

References (33)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824
2. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176:277-84
3. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8
4. King TE, Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. Aphase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92
5. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010;104:1035-41
6. Hyldgaard C, Hilberg O, Bendstrup E. How does comorbid¬ity influence survival in idiopathic pulmonary fibrosis? Respir Med 2014;108:647-53
7. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007;175:875-80
8. Papadopoulos CE, Pitsiou G, Karamitsos TD, Karvounis HI, Kontakiotis T, Giannakoulas G, et al. Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic [corrected] study. Eur Respir J 2008;31:701-6
9. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res 2012;159:218-27
10. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009;103:180-6
11. Corte TJ, Wort SJ, Gatzoulis MA, Engel R, Giannakoulas G, Macdonald PM, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010;36:819-25
12. Lama VN, Martinez FJ. Resting and exercise physiology in intersti¬tial lung diseases. Clin Chest Med 2004;25:435-53
13. Holland AE. Exercise limitation in interstitial lung disease-mech¬anisms, significance and therapeutic options. Chron Respir Dis 2010;7:101-11
14. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;179:402-7
15. Swigris JJ, Swick J, Wamboldt FS, Sprunger D, du Bois R, Fischer A, et al. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2009;136:841-8
16. Schiller NB. Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of the American Society of Echocardiography. Circulation 1991;84:I280-7
17. Schiller NB. Pulmonary artery pressure estimation by Doppler and two-dimensional echocardiography. Cardiol Clin 1990;8:277-87
18. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63
19. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720-35
20. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61
21. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511-22
22. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40
23. American Thoracic Society; American College of Chest Physicians. ATS/ACCPStatement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-77
24. Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary ex¬ercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration 2009;77:3-17
25. Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007;29:185-209
26. Pescatello LS, American College of Sports Medicine. ACSM's guide¬lines for exercise testing and prescription. Philadelphia: Wolters Klu¬wer/Lippincott Williams &Wilkins Health; 2014
27. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATSstatement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7
28. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988;93:580-6
29. Papiris SA, Daniil ZD, Malagari K, Kapotsis GE, Sotiropoulou C, Milic-Emili J, et al. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005;99:755-61
30. Peng S, Li Z, Kang J, Hou X. Cross-sectional and longitudinal con¬struct validity of the Saint George's Respiratory Questionnaire in pa¬tients with IPF. Respirology 2008;13:871-9
31. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304
32. Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Long-term effects of a 12-week exercise training pro¬gram on clinical outcomes in idiopathic pulmonary fibrosis. Lung 2015;193:345-54
33. Vainshelboim B, Oliveira J, Yehoshua L, Weiss I, Fox BD, Fruchter O, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 2014;88:378-88